We investigated the expression of cartilage oligomeric matrix protein (COMP) in normal and rheumatoid arthritis (RA) synovial fibroblasts. In situ hybridization (ISH ) was conducted on synovial specimens from five RA patients applying specific probes for COMP or fibroblast collagen type I. ISH was combined with immunohistochemistry, applying antibodies to the macrophage marker CD68. Ribonuclease protection assay (RPA) and rapid amplification of 3∞-cDNA ends (3∞-RACE) were performed on total RNA from normal and RA synovial fibroblast cultures. Protein extracts from fibroblasts and culture supernatants were compared with synovial fluids and protein extracts from isolated chondrocytes by Western blot utilizing polyclonal and monoclonal antibodies (18-G3 mAb) to COMP. COMP mRNA was detected in fibroblasts of RA synovium by ISH, and in normal and RA synovial fibroblast cultures by RPA. 3∞-RACE demonstrated sequence homology of chondrocyte and synovial fibroblast COMP along the coding sequence. COMP protein was detected in synovial fibroblasts and culture supernatants by immunoblot. Using polyclonal antibodies, the major portion of COMP from fibroblasts and culture supernatants was present as low-molecular-weight (LMW ) bands, corresponding to those found in synovial fluids. These LMW COMP bands, however, were not detected in any of the cells or tissues tested using 18-G3 mAb. In protein extracts from chondrocytes and in COMP purified from cartilage, these LMW bands could not be detected. In conclusion, the data suggest that certain forms of COMP detected in synovial fluid are secreted from synovial fibroblasts and could be distinguished by specific mAbs from COMP secreted by chondrocytes.
C oligomeric matrix protein (COMP) is a was thought to be due to enzymatic degradation of pentameric non-collagenous glycoprotein belonging to COMP within the cartilaginous matrix [10] and/or the the heterogeneous family of thrombospondins [1] .
synovial fluid [9] of inflamed joints. However, other COMP is found abundantly in synovial fluid, reaching studies have also localized COMP in both bovine and concentrations of up to 250 mg/ml. Several investigequine tendons [11, 12] , as well as in human meniscus ators suggested that COMP is mainly produced by and cruciate ligament [9] . Consequently, COMP may articular chondrocytes, and concluded that COMP not be regarded as a cartilage-specific protein. levels in synovial fluid and serum might be related to Recently, preliminary studies reported an expression cartilage damage [2] [3] [4] . Polyclonal antisera against of COMP protein and mRNA in synovium or synovial bovine or human COMP have been produced to estabfibroblasts [13] [14] [15] . lish a test system to monitor cartilage metabolism
The results of the present study confirm and comin joint diseases, including osteoarthritis (OA) and plete these reports. In addition, immunoblot characterrheumatoid arthritis (RA) [5] [6] [7] . In OA, an early istics of COMP from cultured synovial fibroblasts and increase of COMP in serum was reported to be culture supernatants were compared with those of associated with aggressive disease progression [7] .
COMP in synovial fluids, articular cartilage and Interestingly, most recent data, using chondroscopy as isolated chondrocytes. a parameter of cartilage destruction, revealed that serum levels of COMP were not significantly associated METHODS with the progression of cartilage destruction in OA [8] . Moreover, in RA and other inflammatory arthritSynovial tissue samples ides, it has been suggested that, in addition to the Synovial tissue samples were collected from five RA absolute levels of COMP in synovial fluid and serum, patients undergoing wrist and metacarpophalangeal the fragmentation pattern of COMP in synovial fluid joint arthroplasty. All patients fulfilled the revised is of diagnostic importance [9] . This particular pattern criteria of the American College of Rheumatology for the diagnosis of RA [16 ] . Three normal synovial samples were collected: one from the knee of a patient Normal femoral cartilage was obtained from knees cDNA was synthesized using an oligo dT anchor primer and AMV reverse transcriptase according shortly after death and extracted with guanidine-HCl as described previously [9] . Native human COMP was to the manufacturer's recommendations (Boehringer Mannheim). cDNA was amplified by Pfu DNA polypurified from femoral cartilage according to DiCesare et al. [4] . Both were used as standards in the immunomerase applying the anchor primer and the upper primers f588 or f30. The primer sequences were f588 blotting procedure. Polyclonal antibodies to purified COMP were raised in rabbits and shown not to cross-3∞CCT CAA CCC CTG CGT CAA TAC AA-5∞ and f30 3∞-CTT CTT GCG TCC GCC ACA GCC CCT-5∞. react with thrombospondin-1 [9] . The murine monoclonal antibody to native COMP (18-G3) has been
The amplification was conducted with 35 cycles and an annealing temperature of 60°C. Denaturation was developed and characterized earlier [18] . Human chondrocytes were isolated as described by Häuselmann performed at 94°C for 1 min and extension at 72°C for 2 min. The reaction products were run on a 1% et al. [19] . Chondrocytes were kept at −80°C until RNA and protein isolation. Synovial fluids were agarose gel and visualized by ethidium bromide staining. DNA molecular weight marker IV (Boehringer obtained from a healthy individual and two patients with RA, and immediately centrifuged at 450 g for Mannheim) was used as standard. Reaction products were analysed by commercial dideoxy sequencing. 30 min. Synovial fluid cells and cell-free samples were kept at −80°C.
Preparation of cDNA templates and riboprobes
Templates were prepared by linearization of purified
RNA and protein isolations
Total RNA was isolated from cells according to the plasmids. Antisense and sense RNA probes for COMP, collagen type I and collagen type II [21] , and GAPDH method developed by Chomczynski and Sacchi [20] . DNA in the organic phase was removed by precipitawere obtained by in vitro transcription. For in situ hybridization, probes were labelled with digoxigenin tion with ethanol. Protein was recovered by precipitation with isopropyl alcohol, washed in 0.3  (DIG)-11-UTP, the ratio of labelled:unlabelled UTP being 1:2. For ribonuclease protection assay, probes guanidine-HCl and dissolved in 1% sodium dodecyl sulphate (SDS). Supernatants of synovial fibroblast were labelled with [a-32P]UTP. The efficacy of the transcription and the integrity of the probe were vericultures were lyophilized and the pellet dissolved in 1% SDS. Proteinase inhibitors [10 m EDTA, 2 m fied on a 4% polyacrylamide gel under denaturating conditions. phenylmethylsulphonyl fluoride (Sigma) and 2 m N-ethylmaleinimide (Fluka)] were added during the preparation of cell protein and culture supernatants.
In situ hybridization In situ hybridization of synovial tissue was conducted as described by Kriegsmann et al. [22] , with minor Cloning of COMP cDNA fragment from chondrocytes A COMP cDNA fragment (498 bp) was obtained modifications. Frozen sections (4-6 mm) were fixed in 3% buffered paraformaldehyde and acetylated in 0.25% by reverse transcription-polymerase chain reaction (RT-PCR) of chondrocyte RNA and subsequently acetic anhydride/0.1  triethanolamine-HCl. After pre-hybridization, the sections were incubated with the cloned into a plasmid vector. First-strand cDNA synthesis was performed with oligo(dT ) 12-18 primer DIG-labelled RNA antisense probe overnight at 52°C. Unbound probe was digested for 45 min at 37°C with (Gibco BRL) and M-MuLV reverse transcriptase (Boehringer Mannheim), the other reagents being from 10 mg/ml RNase A (Boehringer Mannheim). Sections were incubated in 2 × SSC, 50% formamide for Stratagene (Basel, Switzerland ), according to the manufacturer's protocol. The following primers for human 15 min at 50°C, and washed in 1 × SSC/0.1% SDS, 0.25 × SSC/0.1% SDS and 0.1 × SSC/0.1% SDS each COMP were used: forward 3∞-CCC CGA GTC CGC TGT ATC AA-5∞; reverse 3∞-CCA CAT CCT CCT for 15 min at 50°C. Detection of hybridized probes was performed GCC CTG AG-5∞. cDNA was amplified by PCR under standard conditions using Pfu DNA polymerase immunologically by using anti-DIG antibody Fab fragments linked to alkaline phosphatase and NBT/ (Stratagene). For PCR, we used a three-step protocol with 35 cycles and an annealing temperature of 58°C.
BCIP substrate (Boehringer Mannheim, Rotkreuz, Switzerland ). Non-specific binding was blocked with Denaturation was performed at 94°C for 1 min and 2% normal horse serum. Endogenous alkaline phosphatase was blocked by levamisole added to the substrate.
As negative controls, sections were hybridized with the sense probes or collagen type II probe.
Immunohistochemical double labelling
For double labelling of synovial specimens, after in situ hybridization, immunohistochemistry was performed applying the anti-monocyte/macrophage antibodies (anti-CD68, Dako) in an APAAP technique [22] . Non-specific binding sites were blocked with 4% milk/2% normal goat serum. As negative controls, the primary antibody was replaced by a mouse antibody of the same isotype and concentration (Dako).
Ribonuclease protection assay (RPA)
RPA was performed using reagents from Ambion (AMS Biotechnology, Lugano, Switzerland ) according to the manufacturer's protocol. a-32P-labelled probes were separated on a denaturing urea/4% polyacrylamide gel and eluted. Appropriate amounts of the GAPDH and COMP probes were hybridized to in the presence of 2.5% (v/v) 2-mercaptoethanol. For the range 14-94 kDa, low-molecular-weight (LMW ) standards (Pharmacia) were used (i.e. 94 kDa, phos-3∞-RACE phorylase b; 67 kDa, albumin; 43 kDa, ovalbumin). In Amplification of the 3∞-cDNA ends applying specific addition, in the non-reduced gel, purified human primers reaching up to the 5∞-cDNA end (f30 COMP was used for identification of the 500 kDa position bp 30, f588 position bp 588) and subsequent band. The samples and standards were transferred to sequencing revealed identical amplification products nitrocellulose by electrophoresis according to Towbin for either isolated chondrocytes or RA synovial et al. [24] , the standard stained with Ponceau S solution fibroblasts. Applying the primer f30, the amplification (0.02% in 0.3% trichloroacetic acid; Serva) and antiproduct covers almost the total coding sequence (bp gens detected using polyclonal or monoclonal antibod-30-2299, GenBank No. G602449). ies to COMP, peroxidase-conjugated swine anti-rabbit IgG (Dako) or goat anti-mouse IgG (Jackson In situ hybridization and double labelling Immunoresearch) and by enhanced chemiluminescence
To localize and determine cell types other than ( ECL, Amersham).
fibroblasts within the synovium expressing COMP RESULTS mRNA, in situ hybridization was performed on synovial specimens obtained from five RA patients using RPA riboprobes derived from the same templates as for the A cDNA fragment of COMP was cloned from RPA. Serial sections were processed with antisense human chondrocytes by RT-PCR. Using a riboprobe probes for COMP collagen type I (a fibroblast marker) derived from this fragment, we performed an RPA on and collagen type II (a chondrocyte marker). total RNA prepared from fibroblast cultures of one As presented in Fig. 2a-d , we were able to co-localize normal and three RA synovial samples. We also COMP mRNA-expressing cells with collagen I mRNAincluded total RNA from the myelomonocytic cell expressing fibroblasts in the synovial sublining. In the line U937.
lining areas of RA synovium, little or no expression The RPA on Fig. 1 revealed distinct signals in two of either could be detected. Cells within lymphocytic of the synovial cells and faint signals in the other two.
infiltrates or capillary endothelium were also negative Applying at least the same amount of total RNA from for both probes. Double labelling, as shown in Fig. 3 , U937 cells, as determined by co-hybridization with a revealed that expression of COMP mRNA and the GAPDH probe, no signal for COMP transcripts could be detected. macrophage marker CD68 were mutually exclusive. No signal was detected in synovium with either sense ( b2) fragments. No qualitative difference was found in COMP of fibroblasts from 'healthy' individuals or probes for COMP and collagen I or antisense probe for collagen type II.
patients with RA. Neither in myelomonocytic cells U937 nor in cells obtained from synovial fluid could COMP be detected.
Western blot
Immunoanalysis was performed of protein extracts The murine monoclonal antibody (18-G3), as shown in Fig. 5a , recognized almost exclusively native COMP from human fibroblasts cultured from normal (n = 3) and RA synovium (n = 3), and of culture supernatants from cartilage and isolated chondrocytes in its pentameric form. Regarding fibroblast COMP, this antibody (n = 4), as well as of protein extracted from isolated human chondrocytes and COMP purified from normal bound small amounts of the pentameric form, as did the polyclonal antiserum. The LMW bands (a1 and human femoral cartilage. We applied polyclonal antibodies known to bind human COMP specifically. b1), which represent the major portion of COMP detected with the polyclonal antiserum, could only be In immunoblots under non-reducing conditions, COMP in cartilage extracts or in protein preparations detected in small amounts with the monoclonal antibody in the non-reduced gel. In the synovial fluid from of human chondrocytes was detected as the expected band at 450-500 kDa representing the pentameric proa 'healthy' individual, the monoclonal antibody recognized exclusively some oligomeric forms, but not the tein. Protein extracts from human synovial fibroblasts, as shown in Fig. 4a , presented this band, too. However, smaller bands, which could be detected with the polyclonal antiserum. In RA (n = 3, data not shown), the the major portion consisted of LMW bands at 80 and 90 kDa (a1 and b1, respectively). Using reducing condimonoclonal antibody detected less oligomeric forms. However, as shown in Fig. 5b , the monoclonal antitions, as presented in Fig. 4b , immunoreactive COMP can be seen as the two characteristic 90 and 80 kDa body, under reducing conditions, did not detect any 90 kDa (a2) or 80 kDa (b2) bands either in synovial bands (a2 and b2) in all preparations (cartilage, chondrocytes, fibroblasts and synovial fluid). In contrast fibroblasts, which were clearly recognized by this antibody in cartilage and chondrocytes, and to a lesser to cartilage and chondrocyte preparations, synovial fibroblasts expressed more 90 kDa (a2) than 80 kDa extent in synovial fluid.
F. 3.-In situ hybridization and double labelling: RA synovial sample examined using riboprobes for COMP mRNA and anti-CD68 monoclonal antibody. Expression of COMP mRNA and the macrophage marker CD68 were mutually exclusive.
As illustrated by Fig. 6 , supernatants from synovial The comparative analyses of COMP protein in fibroblast cell lysates, culture supernatants, synovial fibroblast cultures presented the same immunoblot characteristics as the fibroblast preparations. Thus, fluids, cartilage and isolated chondrocytes, applying different antibodies, revealed, as expected, a 450-pentameric forms of COMP, as well as LMW a1 and b1 bands, were detected in both synovial fibroblasts 500 kDa pentameric COMP form in cartilage and chondrocytes. However, using polyclonal antibodies, and culture supernatants. The a1 and b1 bands were similar to those found in synovial fluids.
fibroblast COMP, as well as COMP in culture supernatants, were not only detected as high-molecular-weight DISCUSSION (pentameric) bands, but mainly as LMW bands. The same bands were described in synovial fluids, but not This study supports previous reports showing the production of COMP protein and/or mRNA in in cartilage, by our group [9] . In synovial fluids, these so-called a1 and b1 fragments (80 and 90 kDa, respectsynovium in situ and synovial fibroblasts in vitro [13] [14] [15] . These observations are completed and sumively) had previously been considered as possible products of intra-articular enzymatic degradation of COMP marized as follows. Distinct COMP mRNA expression was detected in the synovial sublining. Lymphocytic released from articular cartilage, although we had not been able to obtain these fragments by in vitro degradainfiltrates and capillary endothelium showed no or only little COMP mRNA expression. As shown by tion of purified cartilage COMP by co-incubation with synovial fluids of RA patients. The detection of the a1 double labelling, expression of COMP mRNA and the macrophage marker CD68 were mutually exclusive. and b1 fragments in fibroblast extracts and culture supernatants was not due to ex vivo degradation of On the other hand, COMP mRNA-expressing cells were strictly co-localized to cells expressing collagen COMP during preparation because the methods used for protein isolation (1) included proteinase inhibitors type I mRNA-in synovium, a marker for fibroblasts. These results were coherent with the RPA by which and/or (2) were the same as used for chondrocytes. Differences between chondrocyte COMP and fibroblast COMP mRNA could only be detected in synovial fibroblast cultures, but not in the myelomonocytic cell COMP were only observed under non-reducing conditions, suggesting an alternative process impairing line U937. By 3∞-RACE, we verified homology along the coding sequence (bp 30-2299) of COMP mRNA pentamer formation in fibroblasts. Interestingly, the a1 and b1 bands of COMP in in fibroblasts with COMP mRNA in chondrocytes. These data confirm that COMP mRNA is expressed fibroblasts and synovial fluids were not reacting with a monoclonal antibody to human cartilage COMP. in synovium and indicate that expression in synovium is largely restricted to fibroblasts.
These findings suggest that there are certain forms of and chondrocytes show exclusively COMP pentamers (P). The pentameric (P) and monomeric-like forms, while immunoreactive synovial fluid shows some oligomeric fragments (O). In synovial COMP in both fibroblasts and synovial fluid shows a high proportion fibroblasts and synovial fluid, the LMW fragments (a1 and b1), of LMW a1 and b1 bands (90 and 80 kDa, respectively). The synovial which represent the majority of COMP detected with the polyclonal fluid also shows significant amounts of oligomers and oligomeric antiserum, are only found at very discrete levels. Under reducing fragments (O). Under reducing conditions (b), the a2 and b2 bands conditions (b), the a2 and b2 bands are not recognized in synovial (90 and 80 kDa, respectively) are detected in all four samples.
fibroblasts, but they are distinctly found in cartilage and chondrocytes, and faintly in synovial fluid after overexposure.
COMP in synovial fluids that are only produced by synovial fibroblasts. It may well be speculated that in synovial fluid and/or serum. Increased amounts of COMP reported in synovial fluids in various joint these forms of COMP differ in the extent of glycosylation, in the polypeptide conformation and/or length.
diseases, as determined with polyclonal antisera, also include fibroblast COMP of affected synovium and For example, removal of the N-terminal region that mediates pentameric arrangement of COMP mononot only COMP released by degenerated cartilage. This may explain the high level of COMP in synovial mers would result in a small shift in the molecular weight of the monomers and impairment of pentamer fluid and/or serum found in patients with RA [25] and early-stage OA [6 ] when radiological changes have not arrangement. Such changes could occur at the posttranslational level.
yet occurred. Specific antibodies to fibroblast COMP and distinct antibodies to cartilage COMP are required In summary, we conclude that certain forms of immunoreactive COMP in synovial fluids originate to differentiate cartilage degeneration from disease activity in the synovium. specifically from synovial fibroblasts. It is evident that the results presented here, although not quantitative, A have to be considered for future evaluations of COMP as a marker for cartilage degeneration and destruction, We thank Dr B. R. Simmen, Schulthess Clinic, for providing synovial tissue and human cartilage, Dr as well as joint inflammation. Thus, the synovium is a further non-cartilage source of COMP that has signi-T. Aigner for collagen type I and II probes, Dr S. Barnum for GAPDH probe, Dr P. E. DiCesare for ficant implications for evaluating the level of COMP
